Tuesday, July 2, 2019

Diabetes Drugs Market Size, Share, Growth, Trends, Analysis and Forecast 2017 To 2025 | Credence Research

According to the latest report published by Credence Research, Inc. “Diabetes Drugs Market By Type Of Therapy (Insulin, Oral Hypoglycemic Drugs (Anti-Diabetes Drugs), Non-Insulin Injectable Anti-Diabetes Drugs, Others) - Growth, Future Prospects, And Competitive Analysis, 2017 - 2025,” the global diabetes drugs market was valued at US$ 49.26 Bn in 2016.
Browse the full report Diabetes Drugs Market - Growth, Future Prospects and Competitive Analysis, 2017–2025 at https://www.credenceresearch.com/report/diabetes-drugs-market
Market Insights                                                  
Diabetes mellitus, often referred as diabetes is one of the largest global health extremities of the 21st century. It is a serious prolonged disease that arises either when pancreas does not secrete sufficient insulin (a hormone that regulates glucose, or blood sugar), or when the body cannot efficiently utilize the insulin it secretes. According to the International Diabetes Federation, approximately 415 million adults currently have diabetes, and by 2040 this pool will rise to 642 million. Due to population growth, unhealthy diets, obesity, aging and sedentary lifestyle, there may be an increase in number of cases in emerging countries. The primary driving force of the global diabetes drugs market is the growing prevalence of diabetes, both the number of cases and prevalence have been progressively increasing over the past few decades. Trend in the growth rate of the population of older persons also reveals the powerful influence on diabetes drugs market.
The market is mainly expected to be driven by large patient pool suffering from diabetes, more R&D in diabetes diagnosis and treatment, minimally or non-invasive products, and improving diagnosis and treatment rates. Moreover, it is observed that growing middle class population, changing demographic profiles, increase in number of consumers with medical insurance, expanding economy, and increasing per capita GDP are also expected to provide massive opportunities for diabetes drugs manufacturers all over the world and especially in Asia Pacific (APAC) region. The global diabetes drugs market is categorized into the insulin, oral hypoglycemic drugs (anti-diabetes drugs), non-insulin injectable anti-diabetes drugs and others. All drugs are delivered orally except exenatide, insulin, liraglutide, and paramlintide.  
Geographically, the global diabetes drugs market is studied for Asia Pacific, Europe, North America, Latin America and Middle East and Africa. In terms of revenue share North America lead the global market and it is anticipated that the region will retain its supremacy during the forecast period. However, the dominance of North America will be prominently challenged by Asia Pacific market due to increase in geriatric population and rising prevalence of diabetes in developing countries like China and India. The global diabetes drugs market is driven primarily by the expanding diabetic population around the world. The Asia Pacific will occupy the more market share in following years. Furthermore, countries such as China also fast growing India and Southeast Asia region will open additional opportunities for market penetration to key companies already having a grip in developed regions.
Download Free PDF Sample Request: https://www.credenceresearch.com/sample-request/58812
Table of Content
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global Diabetes Drugs Market Portraiture
2.1.1. Global Diabetes Drugs Market, by Type of Therapy, 2016 (US$ Bn)
2.1.2. Global Diabetes Drugs Market, by Geography, 2016 (US$ Bn)
Chapter 3. Diabetes Drugs: Market Dynamics and Outlook
3.1. Market Definition and Overview
3.2. Diabetes: Epidemiology
3.3. Drivers
3.4. Challenges
3.5. Opportunities
3.5.1. Attractive Investment Proposition, by Geography, 2016
3.6. Value Chain Analysis
3.7. Major Agreements, Partnerships and Collaborations
3.8. Competitive Landscape
3.8.1. Competitive Landscape, by Key Players, 2016
Chapter 4. Global Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
4.1. Overview
4.2. Attractive Investment Proposition, by Type of Therapy, 2016
4.3. Insulin
4.4. Oral Hypoglycemic Drugs (anti-diabetes drugs)
4.5. Non-insulin Injectable Anti-diabetes Drugs
4.6. Others
4.7. Phase III (Market estimations by 2025)
4.7.1. ISLETS (National Institute of Health (NID) & Health Resource and Services Administration)
4.7.2. ORMD-0801 or Placebo (Oramed, Ltd. & Integrium)
4.7.3. Tauroursodeoxycholic Acid (TUDCA) (Juvenile Diabetes Research Foundation)
4.7.4. Others
4.8. Tabular Presentation of Phase II (Qualitative Information)
4.9. Tabular Presentation of Phase Phase I (Qualitative Information)
Chapter 5. Global Diabetes Drugs Market, by Geography, 2015 – 2025
5.1. Overview
5.2. North America Diabetes Drugs Market Analysis, 2015 – 2025
5.2.1. North America Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
5.2.2. North America Diabetes Drugs Market, by Country, 2015 – 2025 (US$ Bn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Diabetes Drugs Market Analysis, 2015 – 2025
5.3.1. Europe Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
5.3.2. Europe Diabetes Drugs Market, by Country, 2015 – 2025 (US$ Bn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. France
5.3.2.4. Spain
5.3.2.5. Italy
5.3.2.6. Rest of Europe
5.4. Asia Pacific Diabetes Drugs Market Analysis, 2015 – 2025
5.4.1. Asia Pacific Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
5.4.2. Asia Pacific Diabetes Drugs Market, by Country, 2015 – 2025 (US$ Bn)
5.4.2.1. China
5.4.2.2. India
5.4.2.3. Japan
5.4.2.4. Rest of APAC
5.5. Latin America Diabetes Drugs Market Analysis, 2015 – 2025
5.5.1. Latin America Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
5.5.2. Latin America Diabetes Drugs Market, by Country, 2015 – 2025 (US$ Bn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa (MEA) Diabetes Drugs Market Analysis, 2015 – 2025
5.6.1. MEA Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
5.6.2. MEA Diabetes Drugs Market, by Country, 2015 – 2025 (US$ Bn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA
Chapter 6. Company Profiles
6.1.1. AstraZeneca plc
6.1.2. Business Description
6.1.3. Financial Information (Subject to data availability)
6.1.4. Application Portfolio
6.1.5. Key Developments
6.2. Biocon Limited
6.3. Boston Therapeutics, Inc.
6.4. Cadila Healthcare
6.5. Eli Lilly and Company
6.6. GlaxoSmithKline plc
6.7. Johnson & Johnson
6.8. Lupin Limited
6.9. Merck & Co., Inc.
6.10. Novartis International AG
6.11. Pfizer Inc.
6.12. Ranbaxy Laboratories Limited
6.13. Sanofi S.A.
6.14. Takeda Pharmaceutical Company Ltd.
Do Enquiry before Buying for research report: https://www.credenceresearch.com/inquiry-before-buying/58812
About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.
Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
Toll-Free (US/CANADA) Ph.: +1-800-361-8290
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Bone Cement Market | Major players are Zimmer Biomet, Stryker Corporation, DePuy Synthes, Cook Medical, DePuy Synthes, Smith & Nephew

The latest market report published by Credence Research, Inc. “ Bone Cement Market  –  Growth, Future Prospects, and Competitive Analysis,...